Clinical trials and pharmacology of HeberNasvac, a newly registered therapeutic vaccine for chronic hepatitis B: Crossroad of biotechnology, adjuvant strategies and liver immunology
Introduction: Chronic hepatitis B (CHB) infection constitutes a major cause of HCC

